TABLE 2.

Susceptibility of HeLa-CD4/CCR5 cells (clone JC.37) to patient isolates of HIV-1

Patient groupa	Patient no.	HIV titer (foci/0.1 ml of virus stock)b
		JC.37 cells (CCR5+)	HI-J cells (CCR5−)
Plasma isolates from AIDS patients
with advanced disease	1	3.4 × 103	<40
	2	6.0 × 103	<40
	3	4.6 × 103	<40
	4	3.0 × 103	<40
	5	7.2 × 102	1.2 × 102
	7	1.4 × 103	2.4 × 102
	8	3.6 × 103	<40
	9	4.0 × 103	<40
Blood isolates from AIDS patients
with advanced disease	11	2.0 × 103	<40
	12	8.0 × 103	<40
	13	2.0 × 103	<40
	14	7.4 × 103	1.3 × 103
	15	1.0 × 103	<40
	16	7.6 × 102	<40
	17	6.2 × 103	1.4 × 103
	18	1.0 × 104	<40
	19	2.8 × 104	<40
Blood isolates from acute HIV
infection (days 7–47 of illness)	21	2.0 × 103	<40
	22	6.2 × 103	<40
	23	5.6 × 103	<40
	24	6.6 × 103	<40
	25	8.0 × 103	<40
	26	1.7 × 103	<40
	28	7.6 × 103	<40
	29	7.2 × 102	<40

^aIsolates were passaged once on PBMCs after original isolation and stocks produced were titered on CD4-positive HeLa cells expressing or lacking the CCR5 coreceptor. 

^bMost of the primary patient isolates cause no foci on the CCR5-negative HI-J cells. The titers in these cases are given as <40 to account for the virus sample dilutions used in these assays.